• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Layoffs ahead for nearly 300 in Pennsylvania as J&J winds down Animas

October 23, 2017 By Brad Perriello

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) plans to lay off nearly 300 workers in Pennsylvania as it winds down its Animas insulin pump business.

The layoffs for 297 are slated for Animas operations in West Chester and Wayne, Pa., effective Dec. 15, according to a notice filed with the Commonwealth’s Dept. of Labor & Industry. J&J announced the shutdown earlier this month for the 410-worker operation, offering to help some 90,000 Animas patients transfer to products made by rival Medtronic (NYSE:MDT).

Other competitors were quick to pounce. Insulet (NSDQ:PODD) and Dexcom (NSDQ:DXCM) last week floated a joint promotion aimed at luring Animas users.

“We will continue to operate certain functions of the business – including manufacturing, customer and safety support, as examples – for an indeterminate amount of time as we help our patients transition,” Animas spokeswoman Bridget Doherty told the the Philadelphia Inquirer. “Accordingly, we will provide support to impacted employees and their families through the transition.

“A decision and timing to exit markets outside of the U.S. and Canada is pending consultation with relevant works councils,” Doherty said, noting that the Keystone State plants will continue to operate for an “indeterminate amount of time to provide support for our current patients, help them transition, and to support the business outside the U.S. and Canada.”

The Juvenile Diabetes Research Foundation said the market withdrawal for the second-largest insulin pump maker pares the options for diabetes patients.

“It means fewer treatment options,” JDRF CEO Derek Rapp said, according to the newspaper. “Pump choice is critical, and people with type 1 diabetes need the ability to choose the devices that work best for them.”

J&J is also evaluating another of its diabetes businesses, LifeScan, which makes the OneTouch line of blood glucose monitoring products.

Filed Under: Diabetes, Featured Tagged With: animas, Johnson & Johnson

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS